Hema Technology Co., Ltd. has announced its decision to permanently supplement its working capital using part of the funds raised beyond its original target. On March 18, the company revealed plans to allocate 650 million yuan of the excess funds, which represents 13.41% of the total amount raised in excess.
This allocation of funds will not affect the construction needs of the fundraising investment projects. Furthermore, the company has committed not to engage in high-risk investments over the next 12 months. According to the announcement, since its initial public offering, Hema Technology has raised a total of 5.578 billion yuan, with a net amount of 5.406 billion yuan.
The decision to use the excess funds was approved by both the board of directors and the supervisory board and will be submitted for review at the upcoming shareholders’ meeting. For the first three quarters of 2024, Hema Technology reported a revenue of 1.266 billion yuan and a net profit attributable to shareholders of 246 million yuan.
Source: Caizhong She
